Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, Knopp Biosciences is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Bozik played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Knopp Biosciences

Knopp Biosciences seeks to discover, develop, and deliver breakthrough medicines for urgent unmet medical needs. Our goal is to accelerate and advance treatment, change the course of devastating diseases, and improve the lives of patients and their families. Our research has led to an investigational compound in clinical development for immunological disorders, as well as discovery platforms directed to small molecule mediators of epilepsy and neuropathic pain. We bring unmatched energy and a new level of collaboration with practitioners, patient communities, and business partners, allowing us to bridge the distance from the laboratory to the bedside. We understand that every day counts for patients and families with devastating diseases.

To learn more about Knopp Biosciences, visit http://knoppbio.com/

Contact:
Michael Bozik, Chief Executive Officer
412-488-1776
michael.bozik@knoppbio.com
https://www.linkedin.com/in/michael-bozik-6691525/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved